BioCentury
ARTICLE | Financial News

Alzheimer's play Alzheon files for IPO

March 19, 2018 7:24 PM UTC

Alzheon Inc. (Framingham, Mass.) filed to raise up to $80.5 million in an IPO on NASDAQ underwritten by Citigroup, Piper Jaffray, Canaccord Genuity and JMP Securities.

Alzheon plans to start a Phase III trial this year of lead candidate ALZ-801, its oral small molecule prodrug of tramiprosate, to treat Alzheimer's disease. Alzheon obtained ALZ-801's rights in 2013 from Bellus Health Inc. (TSX:BLU), whose Alzhemed tramiprosate failed in Phase III testing for the indication. Alzheon said in 2015 that a subgroup analysis from two completed Phase III studies showed the candidate improved cognition in patients homozygous for apolipoprotein E epsilon 4 (APOE4) (see BioCentury, Nov. 25, 2013)...

BCIQ Company Profiles

Alzheon Inc.